AUTH/3923/6/24 - Complainant v GSK

Alleged unlicensed promotion of Trelegy in a sales aid

  • Case number
    AUTH/3923/6/24
  • Complaint received
    09 June 2024
  • Panel decision
    17 July 2025
  • Appeal hearing
    No appeal
  • Applicable Code year
    2021
  • No breach Clause(s)
  • Additional sanctions

Case Summary

This case was in relation to a representatives’ sales aid. The complainant alleged that it promoted Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol) for an unlicensed indication because it promoted Trelegy Ellipta for use in patients not adequately treated on multiple inhaler triple therapy and Trelegy Ellipta was indicated only for such patients on dual therapy (ICS/LABA or LABA/LAMA).

The outcome under the 2021 Code was:

No Breach of Clause 2

Requirement that activities or materials must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1

Requirement to maintain high standards at all times

No Breach of Clause 11.2

Requirement that promotion of a medicine must be in accordance with the terms of its marketing authorisation and must not be inconsistent with the particulars listed in its summary of product characteristics

This summary is not intended to be read in isolation.
For full details, please see the full case report below.